Rubius Therapeutics: Andrew Oh
Rubius Therapeutics has appointed Andrew Oh as Chief Financial Officer (CFO).
Oh joins Rubius from Leerink Pharmaceutical Investments, and has previously held positions as senior analyst covering global pharmaceutical companies and portfolio manager at Fidelity Investments.
Rubius creates RCT products – genetically engineered, enucleated red cells – to provide allogeneic, ready-to-use cellular therapies for a number of indications, including cancer and enzyme deficiency diseases.
“Andrew’s career-long experience as an investor and analyst at some of the best financial institutions, coupled with his extensive network in the global biopharmaceutical community make him an excellent addition to the Rubius team as the company continues to grow and work to advance the next generation of cellular therapies,” said president Torben Straight Nissen.
Oh told us as CFO at Rubius, he aims to gain support from a strategic/financing perspective on the delivery of breakthrough cell therapies that help patients in a significant way.
Holiday plans?
Oh told us he will be spending the holidays enjoying great food, watching movies, and catching up with family and friends in his home state of Illinois, US.
